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To be cost-effective, therapy to prevent cardiovascular events is best targeted to high-risk patients. Risk scores, 
such as the Framingham score, have been widely used for this 
purpose, but often misclassify risk.1 Measurement of the burden 
of preclinical atherosclerosis has, therefore, been proposed as 
a way to improve cardiovascular prevention.1 Although carotid 
intima-media thickness (IMT) has been widely used for the 
past 30 years, it is increasingly clear that IMT does not truly 
assess atherosclerosis2,3 and is a weak predictor of cardiovas-
cular events,4 that it is not feasible to measure progression of 
IMT within individuals in clinically meaningful time frames, 
and in large groups IMT progression does not predict events.5
Quantification of plaque burden is superior to IMT for sev-
eral reasons: it is a stronger predictor of cardiovascular events,6–8 
change can be reliably measured within individuals in months,9–11 
and progression of total plaque area (TPA) strongly predicts 
stroke, death, and myocardial infarction (MI).12 Measurement of 
TPA has been used to treat arteries rather than risk factors,10 and 
doing so markedly reduces cardiovascular events.13
Volumetric measurement of plaque burden is much more 
closely correlated to coronary calcium than is IMT,14 and 
3-dimensional (3D) measurement of total plaque volume 
(TPV) is much more sensitive to effects of therapy than TPA11; 
compared to IMT, measuring TPV reduces by two orders of 
magnitude the sample size and duration of followup required 
to study effects of new anti-atherosclerotic therapies.11 It is 
expected that measurement of 3D plaque volume will be even 
more useful than TPA in treatment of atherosclerosis.
Here, we report results of the first study to assess prediction 
of cardiovascular events by progression of TPV and the first 
to compare progression/regression of carotid IMT, TPA, and 
TPV in patients attending vascular prevention clinics.
Methods
Study Population
Participants in the study were patients being followed up in the 
Stroke Prevention Clinic or the Premature Atherosclerosis Clinic 
at University Hospital, London, Ontario, Canada. Participants were 
screened for this study by measurement of their carotid TPA.15 We 
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recruited participants with a baseline plaque area between 40 and 
600 mm2 of TPA to ensure that participants would have measurable 
plaque volume and to ensure the ability to measure plaque progres-
sion or regression.
Participants gave written consent to a protocol approved by 
the Western University Human Ethics Research Board. They at-
tended the research clinic at baseline and 1 year later for mea-
surement of the ultrasound phenotypes described below, and 
annually for a total follow-up of 5 years for ascertainment of 
outcomes.
Ascertainment of Outcomes
At each annual visit, participants were queried about any events in the 
previous year. Any report of stroke, transient ischemic attack (TIA), 
MI, or revascularization (stenting, bypass, or endarterectomy of any 
artery) was confirmed by review of the hospital electronic record. For 
patients who could not be contacted to attend for follow-up because 
they had died, death and cause of death were confirmed by contact 
with the primary care physician.
Ultrasound Phenotypes
Carotid TPA, TPV, and IMT were measured at baseline and after 1 
year. The observer (T.W.) was blinded to treatment and time point 
(baseline versus follow-up) for IMT and TPV. Measurements of TPA 
were performed on the ultrasound screen, not offline, so they were 
performed on the day of clinic visits, and, therefore, not blinded as 
to time. The technologists performing the plaque measurements were 
not aware of the treatments.
Table 1. Baseline Characteristics of Study Patients by Progression Group for Plaque Volume
Characteristics Regression* (n=84) Stable* (n=69) Progression* (n=153) P Value†
Age, y 70 (13) 70 (12) 70.5 (13) 0.47
SBP, mm Hg 133 (25) 135 (30) 135 (27) 0.29
DBP, mm Hg 74.5 (16) 76.5 (15) 74.5 (13) 0.60
Total plaque area, mm2 173.5 (112.75) 136.5 (85.75) 157 (114.25) 0.08
Total plaque volume, mm3 336.51 (308.55) 208.1 (226.3) 254.4 (249.37) <0.001
Intima-media thickness, mm 0.96 (0.23) 0.91 (0.18) 0.89 (0.21) 0.037
Carotid stenosis, %‡ 40 (10) 40 (10) 40 (0) 0.35
Total cholesterol, mmol/L 3.96 (1.19) 4.07 (1.10) 3.91 (1.28) 0.85
Triglycerides, mmol/L 1.23 (0.86) 1.22 (0.75) 1.11 (0.84) 0.57
HDL-cholesterol, mmol/L 1.31 (0.49) 1.35 (0.63) 1.345 (0.55) 0.54
LDL cholesterol, mmol/L 1.96 (1.17) 2.0 (0.82) 1.90 (0.98) 0.87
Total homocysteine, µmol/L 9.05 (4.85) 8.7 (3.9) 8.85 (5.77) 0.69
Smoking, pack-y 10 (23.63) 5.53 (27.5) 4.25 (22.19) 0.94
Smoking status
 Never smoked 36.3% 37.3% 34.3% 0.91
 Quit 52.0% 52.9% 59.8% 0.47
 Still smoking 11.8% 9.8% 5.9% 0.33
Female 43.1% 42.2% 43.1% 0.99
Diabetes mellitus 23.5% 19.6% 17.6% 0.57
Previous stroke 28.4% 22.5% 18.6% 0.25
Previous TIA 44.1% 50.0% 36.3% 0.14
Previous MI 14.7% 17.6% 15.7% 0.84
Previous angina pectoris 19.6% 22.5% 23.5% 0.78
Previous AF 3.9% 13.7% 9.8% 0.05
Previous heart failure 2.9% 2.9% 2.0% 0.88
Previous PAD 9.8% 14.7% 16.7% 0.34
Previous carotid endarterectomy 6.9% 3.9% 9.8% 0.25
Previous carotid angioplasty 1.0% 0% 2.9% 0.17
Previous peripheral artery angioplasty 0% 1.0% 2.9% 0.17
Previous coronary angioplasty 5.9% 9.8% 6.9% 0.54
Previous CABG 9.8% 16.7% 6.9% 0.073
Previous lower limb amputation 1.0% 0% 0% 0.37
For progression of total plaque volume (TPV); the median change in TPV was 27mm3; regression was a reduction of TPV by >27 mm3; progression was an increase 
by >27 mm3; and stable plaque volume was a change in either direction by <27 mm3. AF indicates atrial fibrillation; CABG, coronary artery bypass graft; DBP, diastolic 
blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; PAD, peripheral arterial disease; SBP, systolic blood pressure; and 
TIA, transient ischemic attack.
*Continuous variables are reported as median (interquartile range); for categorical variables as percentages.
†Using Kruskal–Wallis H test for continuous variables and using Pearson χ2 test for categorical variables.
‡Maximal internal carotid stenosis on either side.
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Total Plaque Area
TPA was measured by 2 experienced registered vascular technolo-
gists, using Phillips duplex scanners (ATL 5000 HDI with a L12-5, 
50 mm transducer, using Sono-CT compound imaging; Advanced 
Technology Laboratories, Bothel, WA). As previously described,15,16 
plaque was defined as a focal thickening of the intima-media layer, 
>1 mm in thickness. All plaques seen from the clavicle to the angle 
of the jaw, including the right subclavian artery and both common, 
internal and external carotid arteries, were measured. Each plaque 
was measured in a longitudinal view, selecting the plane in which 
the plaque seemed to have the largest footprint, and the cross-sec-
tional area measured by tracing the perimeter of the plaque on the 
screen with a cursor driven by a trackball. The sum of the areas of 
all plaques seen was the TPA. Intraobserver reliability was 94% for 
repeated measurements; interobserver reliability on repeat scanning 
by the 2 technologists was 85%.15
Total Plaque Volume
As previously described,17,18 TPV was measured with a software up-
date permitting semiautomated segmentation of the lumen.19,20 3D 
US images were acquired by translating the ultrasound transducer 
(L12-5, 50 mm, Philips, Bothel, WA) in a transverse orientation (per-
pendicular to the axis of flow) along the neck of the patient for ≈8 
seconds an approximate distance of 4.0 cm, whereas video frames 
from the duplex scanner were digitized using 3DEchotec equipment 
(General Electric Medical Systems, Halbergmoos, Germany) coupled 
to the ATL HDI 5000 scanner. Cross-sectional slices were acquired at 
the rate of ≈30 slices/s, and saved to a computer workstation. The ori-
entation and speed of the transducer was adjusted so that the resulting 
transverse 2D images were approximately parallel to each other with 
a mean spatial interval of ≈0.15 mm. The acquired 2D images were 
reconstructed immediately into a 3D US image and displayed using 
3D viewing software (3DQuantify, Robarts Imaging Laboratories, 
London, Canada).
A semiautomated approach that uses 2 planes was used to quantify 
carotid plaque volume as previously described.20 Plaque was defined 
as focal thickening >1 mm of the intima-media in the longitudinal 
view. Briefly, a longitudinal axis was set parallel to the axis of flow 
in the common and internal carotid arteries. Plaques were measured 
in the common carotid and internal carotid, from 1.5 cm below the 
bifurcation to 1 cm above the bifurcation. In a longitudinal view, the 
plane in which the plaque seemed to have the largest footprint was 
selected to identify the length and end points of the plaque. Along this 
length the plaque boundary was identified at 25%, 50%, and 75% of 
the total length using a second plane perpendicular to arterial blood 
flow. Although the longitudinal view identified the length and end 
points of the plaque, the perpendicular cross-sectional view defined 
plaque morphology. Individual plaque volumes within the same ar-
tery were summed to generate a TPV for 1 side. Intraobserver reli-
ability for measurement of TPV is 94%, and interobserver reliability 
is 93%.9 As previously described,18 carotid TPVs were summed from 
left and right carotid arteries to generate a TPV for each subject at a 
particular time point.
Intima-Media Thickness
As previously described,21 IMT was measured from lateral image 
planes extracted from the 3D US images. Images were included for 
analysis only if there was a clear intima-media layer present for 
Table 2. Percentage of Patients Taking Various Classes of Cardiovascular Medications
Regression Stable Progression P Value*
Antiplatelet agent 82.4 80.4 73.5 0.27
Anticoagulant 4.9 16.7 14.7 0.022
Antihypertensive drug 88.2 91.2 87.3 0.65
 ACE inhibitor 49.0 54.9 45.1 0.37
 ARB 20.6 19.6 31.4 0.091
 β Blocker 29.4 39.2 36.3 0.32
 CCB 33.3 30.4 51.0 0.005
 Diuretic 54.9 45.1 58.8 0.13
 Aliskiren 0 0 1.0 0.37
 Alpha blocker 2.9 6.9 4.9 0.43
Oral DM 14.7 7.8 12.7 0.29
Insulin 2.0 4.9 4.9 0.46
Lipid-lowering drug 96.1 92.2 93.1 0.48
 Statin 90.2 85.3 85.3 0.49
  Low dose† 17.6 18.6 25.5 0.32
  Medium dose† 60.8 47.1 46.1 0.063
  High dose† 11.8 19.6 13.7 0.26
 Ezetimibe 49.0 38.2 52.9 0.093
 Fibrate 14.7 17.6 19.6 0.65
 Niacin 7.8 4.9 8.8 0.53
NSAIDs 8.8 7.8 5.9 0.72
Vitamin B12 76.5 78.4 76.5 0.93
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; NSAIDs, 
nonsteroidal anti-inflammatory drugs; Oral DM, oral hypoglycemic drug; and statin, HMG CoA reductase inhibitor.
*Exact χ2 test.
†Statin dose ranges: (1) low dose: atorvastatin 10 mg, simvastatin 10 to 20 mg, rosuvastatin 5 mg, fluvastatin 20 to 80 mg, and 
pravastatin 10 to 40 mg; (2) medium dose: atorvastatin 20 to 40 mg, rosuvastatin 10 to 20 mg, and simvastatin 40 mg; and (3) high 
dose: atorvastatin 80 mg and rosuvastatin 40 mg.
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measurement. In the 3D US image, a lateral plane parallel to the 
axis of the common carotid artery was selected from the location 
of the carotid bulb marked, and contrast and brightness optimized 
for viewing the intima-media layer. Calibration lines were drawn 
over a length of 10 mm, and a 24-bit bitmap was saved and im-
ported into Prowin 24.0 (Medical Technologies International Inc, 
Palm Desert, CA). After calibration, measurements were obtained 
from a 10-mm segment of the far wall of the common carotid ar-
tery, 5 mm from the carotid bulb. A different segment was chosen 
if plaque was identified in that location (defined as focal thickening 
>1 mm). In some cases where there was diffuse thickening, the IMT 
exceeded 1 mm. A mouse-driven cursor was used to place 10 to 15 
points along the media-adventitia and the intima-lumen boundary. 
The distance between the curves defined by the points was IMT. 
Measurements were repeated 3× per image, and the mean was cal-
culated. Intraobserver reliability was 97.1%; interobserver reliabil-
ity was not assessed.
Statistical Methods
Analyses were performed using IBM SPSS Statistics version 20 (IBM, 
Chicago, IL). A Kolmogorov–Smirnov test of normality showed that 
continuous variables were not normally distributed, hence median 
and interquartile range were reported for descriptive statistics, and a 
Kruskal–Wallis test was used to test for differences among groups. 
Categorical variables were reported as percentages and a χ2 test (Exact 
test) used to test for differences. Progression or regression of TPA, TPV, 
or IMT was defined by tertiles of change from baseline to 1 year later. 
Kaplan–Meier survival analysis was performed to assess event rate by 
progression, stability, or regression of the ultrasound variables; com-
parisons among groups were by the log-rank test pooled over strata. 
Cox regression, using a backward stepwise Wald approach, was used to 
evaluate effects of covariates: age, sex, smoking status, serum total cho-
lesterol, triglycerides, high-density lipoprotein cholesterol, low-density 
lipoprotein cholesterol, systolic blood pressure, and diabetes mellitus.
Results
There were 349 patients enrolled in the study. The median 
duration of follow-up was 3.17 years, with a maximum of 
5.0 and a minimum of 0.07 years. The timing of dropouts 
and events is shown in Figure IV in the online-only Data 
Supplement. During 5 years, there were 21 dropouts. For each 
case the first qualifying event was used in the survival analyses. 
There were 50 first events: 20 vascular deaths, 11 strokes, 13 
TIAs, and 6 MIs. Timing of first events is shown in Figure IV 
in the online-only Data Supplement. Some participants had >1 
event; Table IV in the online-only Data Supplement shows the 
timing of all 55 events.
Baseline characteristics are shown in Table 1, and base-
line medications being taken by the participants are shown in 
Table 2, both grouped by regression, stability, or progression 
of TPV. Table V in the online-only Data Supplement shows 
tertiles of progression of TPV, TPA, and IMT.
The distribution of baseline IMT, TPA, and TPV, and the 
distribution of change from baseline to 1 year later for the 3 
phenotypes are shown in Figure V in the online-only Data 
Supplement. Data on 1-year progression/regression were avail-
able in 323 cases for TPA and in 306 cases for TPV and IMT.
Assessed by Pearson correlation (R), baseline TPV was 
strongly correlated with TPA (R=0.645; P=0.001), but only 
weakly correlated with IMT (R=0.189; P=0.001). This is 
illustrated in Figure VI in the online-only Data Supplement. 
Accordingly, TPA was also weakly correlated with IMT 
(R=0.282; P=0.001). However, there was no significant cor-
relation between progression/regression of TPA versus TPV 
Figure 1. Risk of stroke, transient ischemic attack (TIA), or death 
by progression/regression of total plaque volume. Kaplan–Meier 
1-survival curves of stroke, TIA, or death over 5 years in partici-
pants with regression, stable plaque, or progression (defined by 
the tertiles of change in plaque volume from baseline to 1 year 
later). Tertiles are shown in Table IV in the online-only Data Sup-
plement. The log-rank P value was 0.001 across the 3 groups.
Figure 2. Risk of stroke, transient ischemic attack (TIA), or death 
by progression/regression of total plaque area. Kaplan–Meier 
1-survival curves of stroke, TIA, or death over 5 years in partici-
pants with regression, stable plaque, or progression (defined by 
the tertiles of change in TPA from baseline to 1 year later). Ter-
tiles are shown in Table IV in the online-only Data Supplement. 
The log-rank P value was 0.143 across the 3 groups.
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(R=−0.035; P=0.549), TPA versus IMT (R=−0.024; P=0.680), 
or TPV versus IMT (R=0.042; P=0.460).
In this population chosen by the presence of substantial 
plaque, the baseline burden of IMT, TPA, or TPV did not pre-
dict events. Survival free of any cardiovascular event (stroke, 
vascular death, TIA, or MI) and survival free of stroke, TIA, 
or vascular death were significantly predicted by progression/
regression of TPV, as shown in Figure 1. In Cox regression 
analysis (backward stepwise Wald), at the final step (step 9), the 
only remaining predictors were baseline systolic blood pres-
sure (P=0.086) and progression/regression of TPV (P=0.001).
Participants with progression of TPA from baseline to 1 
year later had more events; this approached significance for 
stroke/death/TIA (P=0.097), as shown in Figure 2, but not 
for any CV event (P=0.143). Prediction of any CV event by 
progression/regression of TPA was intermediate between pre-
diction by TPV and IMT, as shown in Figures VII to IX in 
the online-only Data Supplement. In Cox regression with TPA 
change and baseline covariates, only age (P=0.034) and smok-
ing status (P=0.031) remained in the model at the final step 
(step 7). Similarly, as shown in online supplementary figures 
10-12, progression of TPV predicted stroke/death/myocardial 
infarction (P=0.007), progression of TPA did not (P-0.59), nor 
did progression of IMT (P=0.13).
However, progression/regression of IMT did not pre-
dict stroke/TIA/death as shown in Figure 3 nor did it predict 
any cardiovascular event (Figure IX in the online-only Data 
Supplement). In Cox regression with baseline covariates as listed 
in Methods, smoking status (P=0.021), triglycerides (P=0.009), 
high-density lipoprotein cholesterol (P=0.044), and IMT change 
(P=0.004) were significant predictors of events, but as shown in 
Figure 3 and Figure IX in the online-only Data Supplement, the 
relationship to IMT change was inverse because IMT regression 
was associated with a higher risk of events.
Discussion
To our knowledge, this is the first study of TPV progression as 
a predictor of cardiovascular outcomes, and the first to com-
pare progression of IMT, TPA, and TPV in the same partici-
pants. The Tromsø study22 compared progression of IMT and 
TPA with regard to coronary risk factors, but did not measure 
TPV, and to date have not reported on prediction of events 
by progression of IMT and TPA. Sillesen et al14 showed that 
plaque burden measured by a 3D probe (but not strictly plaque 
volume, as the probe was moved along the artery) was much 
more strongly correlated with coronary calcium score than 
was IMT; they did not measure TPA.
We found that progression of TPV strongly predicted car-
diovascular events, and the prediction remained significant 
after adjustment for coronary risk factors in Cox regression. 
Surprisingly, it was regression of IMT rather than progression 
that predicted events, a finding that strengthens the growing 
consensus that IMT measured in the far wall of the com-
mon carotid at a site where there is no plaque should not be 
regarded as truly representing atherosclerosis.2,3,22–24 Possible 
reasons for this finding, and for the weak correlation between 
IMT and plaque, have been discussed previously25,26; IMT is a 
different phenotype that probably represents mainly hyperten-
sive medial hypertrophy, and probably does not truly represent 
atherosclerosis.2 Another possible reason is that for technical 
reasons we measured different segments of the carotid arter-
ies with the 3 methods. Progression of TPA weakly predicted 
stroke/TIA/death but not the all cardiovascular events, and 
prediction of risk was not significant after adjustment for cor-
onary risk factors.
A limitation of the study was the relatively small sample, 
which was determined by the funding available. The a priori 
sample size calculation had been that 350 participants fol-
lowed for a mean of 4.7 years would give an adequate sample 
size to show differences among the ultrasound phenotypes 
with regard to prediction of cardiovascular events. This was 
based on data from our 2002 report15 and was consistent with 
the sample in a study of TPA, IMT, and endothelial function 
as predictors of events in patients with coronary artery disease 
by Chan et al.27 However, the finding that progression of TPV 
significantly predicted events in such a small sample supports 
the contention that measurement of TPV is a powerful tool for 
assessing clinically relevant effects of therapy.
It should be noted that the study population was powerful, 
despite its small size, because all participants had substantial 
carotid plaque, and the number of events was relatively high. 
In our 2002 study15 of TPA and TPA progression, in which 
approximately half the participants had little or no plaque at 
baseline, there were 166 vascular events among 1686 participants 
(9.8%) followed for an average of 2.5 years (about as many 
events as in the first 10 years of the Framingham Heart Study); in 
this study population, there were first vascular events in 15.8% 
of participants during a median follow-up of 3.17 years.
Figure 3. Risk of stroke, transient ischemic attack (TIA), or death 
by progression/regression of intima-media thickness. Kaplan–
Meier 1-survival curves of stroke, TIA, or death >5 years in partic-
ipants with regression, stable plaque, or progression (defined by 
the tertiles of change in IMT from baseline to 1 year later). Tertiles 
are shown in Table IV in the online-only Data Supplement. The 
log-rank P value was 0.886 across the 3 groups.
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In 2012, the Rotterdam study28 and the MESA study29 
both showed that coronary artery calcium, but not IMT, 
improved risk prediction and risk reclassification beyond a 
Framingham risk score. Although a single coronary artery 
calcium might be useful for reclassifying patients to higher 
risk so that they can be appropriately chosen for more inten-
sive therapy, concern about radiation with repeated scans 
precludes its use for management of patients. Carotid TPA 
has been used successfully to treat arteries instead of risk 
factors,10 and this approach markedly reduced risk among 
high-risk patients with asymptomatic carotid stenosis.30 
Brook et al31 found that TPA was more closely related to 
coronary stenosis than IMT, coronary calcium, or CRP, and 
Johri et al32 found that plaque volume was more sensitive 
than plaque thickness for prediction of coronary stenosis. 
Our findings suggest that measurement of TPV will be a use-
ful approach to treating high-risk patients; this hypothesis 
will need to be tested in a clinical trial. It should be noted 
that our management of patients was not protocol-based but 
was based on our previously reported approach10 to treating 
arteries instead of treating risk factors.
Measurement of TPV progression will also be useful for 
computing quantitative traits of atherosclerosis for genetic 
studies because as previously discussed,33 age accounts for 
most of the explained variance in baseline plaque phenotypes, 
but is only a weak predictor of progression.
As genetic approaches identify new therapeutic targets 
for atherosclerosis,34,35 it will be important to have methods 
to study effects of new therapies on atherosclerosis as proof-
of-principle, before going on to very large and costly studies 
on the basis of reduction of events. Our findings support 
the recommendation3 that measurement of TPV is a cost-
effective way to assess new therapies for atherosclerosis.
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